Key result
Translational research in rare neuromuscular diseases highlights the critical need for well-defined inclusion criteria, appropriate matching, and clinically relevant endpoints to ensure trial success.
Why the study?
Spinal Muscular Atrophy and Duchenne Muscular Dystrophy present case studies for translating preclinical research into clinical work, requiring key trial design features to maximize success for rare neuromuscular diseases.
This review highlights critical considerations for clinical trial design in rare neuromuscular diseases, emphasizing the importance of patient selection, appropriate comparators, and meaningful outcome measures to maximize trial success.
Manage expectations when applying SMA/DMD approvals beyond selected trial cohorts; leaves open how external controls and registries should guide future rare-disease trials.
Spinal Muscular Atrophy (SMA) and Duchenne Muscular Dystrophy (DMD), two of the most common, child onset, rare neuromuscular disorders, present a case study for the translation of preclinical research into clinical work. Over the past decade, well-designed clinical trials and innovative methods have led to the approval of several novel therapies for SMA and DMD, with many more in the pipeline. This review discusses several features that must be considered during trial design for neuromuscular diseases, as well as other rare diseases, to maximise the possibility of trial success using historic examples. These features include well-defined inclusion criteria, matching criteria, alternatives to placebo-controlled trials and the selection of trial endpoints. These features will be particularly important in the coming years as the investigation into innovative therapy approaches for neuromuscular diseases continues.
No takes yet. Share an insight, caveat, or question.
Stimpson et al. (2021) conducted a review in Spinal Muscular Atrophy (SMA) and Duchenne Muscular Dystrophy (DMD). Clinical trial design strategies was evaluated. Translational research in rare neuromuscular diseases highlights the critical need for well-defined inclusion criteria, appropriate matching, and clinically relevant endpoints to ensure trial success.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: